1.
Iwane, S., Nemoto, W. (co-first author), Miyamoto, T., Hayashi,
T., Tanaka, M., Uchitani, K., Muranaka, T., Fujitani, M., Koizumi, Y., Hirata,
A., Tsubota, M., Sekiguchi, F., Tan-No, K., Kawabata, A.* (2024) Clinical
and preclinical evidence that angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers prevent diabetic peripheral neuropathy. Sci. Rep., 14, 1039. PubMed
2.
Kasanami, Y., Yamamoto, T., Miyamoto, T., Matzno, S.,
Sakakibara, M., Iwaki, M., Kawabata,
A.* (2023) Characterization of potentially inappropriate medications
that need special attention in the elderly with dementia by analyzing pharmacy
claims data. Biol.
Pharm. Bull., 46, 1699-1705. PubMed
3.
Tomita, S., Sekiguchi,
F., Tsubota, M., Kawabata, A.* (2023) Dietary
zinc deficiency induces Cav3.2-dependent nociceptive
hypersensitivity in mice. Biol. Pharm. Bull., 46, 1343-1346. PubMed
4.
Tomita, S., Sekiguchi,
F., Naoe, K., Shikimi, S., Kasanami, Y., Ohigashi, M., Tsubota, M., Kawabata, A.* (2023) Cav3.2-dependent
hyperalgesia/allodynia following intrathecal and intraplantar zinc chelator
administration in rodents. J. Pharmacol. Sci., 152, 86-89. PubMed
5.
Sekiguchi, F., Koike, N. (co-first
author), Shimada, Y. (co-first author), Sugimoto, K., Masuda, H., Nakamura, T.,
Yamaguchi, H., Tababe, G., Marumoto, S., Kasanami, Y., Tsubota, M., Ohkubo, T., Yoshida, S., Kawabata, A.* (2023) A hydrolysate of
poly-trans-[(2-carboxyethyl)germasesquioxane]
(Ge-132) suppresses Cav3.2-dependent pain by sequestering exogenous
and endogenous sulfide. Redox
Biol., 59, 102579. PubMed Outstanding
paper
6.
Maeda, T., Sekiguchi,
F. (co-first author), Mitani, K., Yamagata, R., Tsubota, M., Yoshida, S., Kawabata, A.* (2023) Opioid modulation of T-type Ca2+
channel-dependent neuritogenesis/neurite outgrowth through the prostaglandin E2/EP4
receptor/protein kinase A pathway in mouse dorsal root ganglion neurons. Biochem. Biophys. Res. Commun., 639, 142-149. PubMed
7.
Kasanami, Y., Ishikawa, C., Kino, T., Chonan, M., Toyooka, N.*,
Takashima, Y., Iba, Y., Sekiguchi, F.,
Tsubota, M., Ohkubo, T.,
Yoshida, S., Kawase, A., Okada, T.*, Kawabata,
A.* (2022) Discovery of Pimozide Derivatives as Novel T-type Calcium
Channel Inhibitors with Little Binding Affinity to Dopamine D2
Receptors for Treatment of Somatic and Visceral Pain. Eur. J. Med. Chem., 243, 114716. PubMed
8.
Miyamoto, T., Domoto, R. (co-first author), Sekiguchi, F., Kawaguchi, R., Nishimura, R., Matsuno, M., Tsubota, M., Fujitani, M.,
Hatanaka, S., Koizumi, Y., Wang, D., Nishibori, M., Kawabata, A.* (2022) Development of hepatic impairment
aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin
treatment: Evidence from clinical and preclinical studies. J. Pharmacol. Sci., 148 (3), 315-325. PubMed
9.
Domoto, R., Sekiguchi,
F. (co-first author), Kamaguchi, R., Iemura, M., Yamanishi, H., Tsubota, M., Wang, D.,
Nishibori, M., Kawabata, A.* (2022)
Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages
and peripheral neuropathy. J. Pharmacol. Sci., 148 (1),
156-161. PubMed
10.
Ieda, S., Miyamoto, T. (co-first author), Hosomi, K., Takegami,
M., Kawabata, A.* (2022) Identification of remaining life
expectancy less than two weeks by CRP/albumin ratio, prognostic nutritional
index, fibrosis-4 index and albumin-bilirubin score in terminal cancer
patients. J.
Palliat. Med., 25 (4), 570-576. PubMed
11.
Hiramoto, S., Asano, H., Miyamoto, T., Takegami, M., Kawabata, A.* (2021) Risk
factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in
paclitaxel-treated female cancer survivors: A retrospective study in Japan. PLOS One, 16 (12), e0261473. PubMed
12.
Tsubota,
M., Miyazaki, T., Ikeda, Y., Hayashi, Y., Aokiba, Y., Tomita, S., Sekiguchi, F., Wang, D., Nishibori,
M., Kawabata, A.* (2021)
Caspase-dependent HMGB1 release from macrophages participates in peripheral
neuropathy caused by bortezomib, a proteasome-inhibiting chemotherapeutic
agent, in mice. Cells, 10, 2550. PubMed
13.
Hayashi, T., Miyamoto, T., Nagai, N., Kawabata, A.* (2021) Development of diabetes mellitus
following hormone therapy in prostate cancer patients is associated with early
progression to castration resistance. Sci. Rep., 11, 17157. PubMed
14.
Domoto, R., Sekiguchi,
F. (co-first author), Tsubota,
M. (co-first author), Kawabata,
A.* (2021) Macrophage as a peripheral pain regulator. Cells, 10, 1881. (Review) PubMed
15.
関口富美子、川畑篤史*(2021)プロテアーゼ活性化受容体をターゲットとした臨床応用. Clin. Neurosci., 39,
684-686. (Review)
16.
坪田真帆、川畑篤史*(2021)プロテアーゼ活性化受容体の生理的および薬理的作用.Clin. Neurosci., 39,
521-523. (Review)
17.
川畑篤史*(2021)プロテアーゼ活性化受容体の種類.Clin. Neurosci., 39,
390-393. (Review)
18.
Miyamoto, T., Hiramoto, S. (co-first author), Kanto, Y., Tsubota, M., Fujitani, M.,
Furuyama, H., Hatanaka, S., Sekiguchi,
F., Koizumi, Y., Kawabata,
A.* (2021) Estrogen decline is a risk factor for paclitaxel-induced
peripheral neuropathy: clinical evidence supported by a preclinical study. J. Pharmacol. Sci., 146, 49-57. PubMed
19.
Tsubota,
M., Matsui, K. (co-first author), Fukushi, S., Okazaki, K., Sekiguchi, F., Kawabata, A.* (2021) Effects of
bepridil and pimozide, existing medicines capable of blocking T-type Ca2+
channels, on visceral pain in mice.
Biol.
Pharm. Bull., 44, 461-464. PubMed
20.
Sekiguchi,
F., Kawabata,
A.* (2021) Role of HMGB1 in chemotherapy-induced peripheral neuropathy.
Int.
J. Mol. Sci., 22 (1), 367. (Review) PubMed
21.
Tsujita, R., Tsubota, M.
(co-first author), Sekiguchi, F., Kawabata, A.*
(2021) Role of high mobility group box 1 and its modulation by
thrombomodulin/thrombin axis in neuropathic and inflammatory pain. Br. J. Pharmacol., 178, 798-812. (Review) PubMed
22.
Tomita, S., Sekiguchi, F. (co-first author), Kasanami, Y., Naoe, K., Tsubota, M., Wake, H.,
Nishibori, M., Kawabata, A.*
(2020) Cav3.2 overexpression in L4 dorsal root ganglion neurons
after L5 spinal nerve cutting involves Egr-1, USP5 and HMGB1 in rats: an
emerging signaling pathway for neuropathic pain. Eur. J. Pharmacol.,
888, 173587. PubMed
23.
Tsubota,
M., Matsui, K., Nakano, M., Kajitani, R., Ishii,
Y., Tomochika, K., Nishikawa, Y., Fukushi, S., Yamagata, A., Sekiguchi, F., Okada, T.,
Toyooka, N., Kawabata, A.*
(2020) Essential role of Cav3.2 T-type calcium channels in
butyrate-induced colonic pain and nociceptor hypersensitivity in mice. Eur. J. Pharmacol.,
887, 173576. PubMed
24.
Miyamoto, T.*, Fujitani, M., Hatanaka, S.,
Koizumi, Y., Kawabata, A.
(2020) Use of transdermal fentanyl and elevated gamma-glutamyl transpeptidase
levels are associated with increased total daily dose of opioid. Jpn J Pharm Palliat Care Sci,
13, 105-110.
25.
Hiramoto, S., Tsubota, M. (co-first author), Yamaguchi, K., Okazaki, K.,
Sakaegi, A., Toriyama, Y., Tanaka, J., Sekiguchi,
F., Ishikura, H., Wake, H., Nishibori, M., Nguyen, H.D., Okada, T.,
Toyooka, N., Kawabata,A.*
(2020) Cystitis-related bladder pain involves ATP-dependent HMGB1 release from
macrophages and its downstream H2S/Cav3.2 signaling in
mice. Cells, 9, 1748. PubMed
26.
Matsui, K., Mukai, Y., Sakakura, K., Wada,
K., Nakamura, T., Kawabata, A.,
Terakawa, N., Hayakawa, N., Kusano, K., Hosomi, K., Yokoyama, S., Takada, M.*
(2020) Relationship between serum bepridil concentration and corrected QT
interval. Int.
J. Clin. Pharmacol. Ther.,
59 (1), 63-70. PubMed
27.
Hayashi, T., Kawaguchi, H., Eifuku, T.,
Matsuoka, H., Kawabata, A.,
Nagai, N.* (2020) Changes in percutaneous absorption of fentanyl patches in
rats treated with a sebum-like secretion. Chem. Pharm. Bull., 68 (9), 879-884. PubMed
28.
Okamoto, H., Yoshikawa, T., Takeuchi, K.,
Deguchi, S., Hatakenaka, Y., Matsuoka, H., Kawabata, A., Nagai, N.*
(2020) A combination of cryopreservation and kneading maintains the usability
of Mohs past. Chem. Pharm. Bull., 68 (6), 516-519. PubMed
29.
Irie, Y., Tsubota, M.
(co-first author), Maeda, M., Hiramoto, S., Sekiguchi, F.,
Ishikura, H., Wake, H., Nishibori, M., Kawabata, A.* (2020) HMGB1
and its membrane receptors as therapeutic targets in an intravesical substance
P-induced bladder pain syndrome mouse model. J.
Pharmacol. Sci., 143 (2), 112-116. PubMed
30.
Matsui, K., Terada, Y., Tsubota, M.,
Sekiguchi, F., Kawabata, A.* (2020) Tacrolimus, a
calcineurin inhibitor, promotes capsaicin-induced colonic pain in mice. J.
Pharmacol. Sci., 143 (1), 60-63. PubMed
31.
林 友典、高科結衣、川口陽奈子、永福 紡、松岡 寛、川畑篤史、長井紀章*
(2019) フランツ型拡散セルを用いた市販フェンタニルテープの経皮吸収性の評価:温熱条件下における薬物放出性と皮膚透過性の測定.医療薬学, 45, 416-422.
32.
Tsubota, M.,
Fukuda, R., Hayashi, Y., Miyazaki, T., Ueda, S., Yamashita, R., Koike, N., Sekiguchi,
F., Wake, H., Wakatsuki, S., Ujiie, Y., Araki, T., Nishibori, M., Kawabata,
A.* (2019) Role of non-macrophage cell-derived HMGB1 in
oxaliplatin-induced peripheral neuropathy and its prevention by the
thrombin/thrombomodulin system in rodents: negative impact of anticoagulants. J. Neuroinflammation., 16 (1), 199. PubMed
33.
Matsui, K., Tsubota, M. (co-first author), Fukushi, S., Koike, N.,
Masuda, H., Kasanami, Y., Miyazaki, T., Sekiguchi,
F., Ohkubo, T., Yoshida, S., Mukai, Y., Oita, A., Takada, M., Kawabata, A.* (2019) Genetic
deletion of Cav3.2 T-type calcium channels abolishes H2S-dependent
somatic and visceral pain signaling in C57BL/6 mice. J.
Pharmacol. Sci., 140,
310-312. PubMed
34.
川畑篤史*、坪田真帆、関口富美子、辻田隆一 (2019) HMGB1を標的とする化学療法誘発性末梢神経障害の予防.日薬理誌.,
154, 236-240. (Review) PubMed
35.
関口富美子*、川畑篤史 (2019)
前立腺がん細胞におけるCav3.2
T型カルシウムチャネルの役割.日薬理誌., 154, 97-102. (Review) PubMed
36.
坪田真帆*、川畑篤史 (2019) 硫化水素によるCav3.2を介する疼痛シグナルの調節.日薬理誌., 154, 128-132. (Review) PubMed
37.
Nguyen, H.D.*, Okada, T., Sekiguchi, F., Tsubota, M., Nishikawa, H., Kawabata, A., Toyooka, N. (2019)
Prenylflavanones as novel T-type calcium channel blockers useful for pain
therapy. Nat. Prod. Commun., 14 (9)
(https://doi.org/10.1177/1934578X19873441). (Review) Journal HP
38.
Tsubota,
M.,
Uebo, K., Miki, K., Sekiguchi, F.,
Ishigami, A., Kawabata, A.*
(2019) Dietary ascorbic acid restriction in GNL/SMP30-knockout mice unveils the
role of ascorbic acid in regulation of somatic and visceral pain sensitivity. Biochem. Biophys. Res. Commun., 511, 705-710. PubMed
39.
Matsuda, S., Nishikawa, H. (co-first author), Fukatsu, A., Kurokawa, Y., Tsubota, M., Sekiguchi, F., Tokuyama, S., Kawabata, A.* (2019) NNC 55-0396,
a T-type calcium channel blocker, protects against the brain injury induced by
middle cerebral artery occlusion and reperfusion in mice. J. Pharmacol. Sci., 140, 193-196. PubMed
40.
Tomita, S., Sekiguchi, F., Deguchi, T., Miyazaki, T., Ikeda, Y., Tsubota, M., Yoshida, S.,
Nguyen, H.D., Okada, T., Toyooka, N., Kawabata,
A.* (2019) Critical role of Cav3.2 T-type calcium channels
in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting
chemotherapeutic agent, in mice. Toxicology, 413, 33-39. PubMed
41.
坪田真帆、川畑篤史* (2019) 内臓痛におけるマクロファージ由来HMGB1の役割と治療標的分子としての可能性.Pain Res., 34, 24-30. (Review)
42.
Koizumi, Y.*, Ishiwata, S., Inoue, T.,
Takada, M., Kawabata, A.,
Kotake, T. (2019) Investigation of the levels of ifosfamide vaporized from
powder and solution. Jpn.
J. Occup. Med. Traumatol. 67, 95-99.
43.
Miyamoto, T.*, Fukuyama, H., Hatanaka, S.,
Fujitani, M., Koizumi, Y., Kawabata,
A. (2019) The C-reactive protein/albumin
ratio is useful for predicting short-term survival in cancer and non-cancer
patients. J. Palliat. Med., 22, 532-537. PubMed
44.
Sekiguchi,
F.,
Domoto, R. (co-first author), Nakashima, K., Yamasoba, D., Yamanishi, H., Tsubota, M., Wake, H.,
Nishibori, M., Kawabata, A.*
(2018) Paclitaxel-induced HMGB1 release from macrophages and its implication
for peripheral neuropathy in mice: evidence for a neuroimmune cross talk. Neuropharmacology,
141, 201-213. PubMed
45.
Nguyen, H.D., Okada, T., Kitamura, S.,
Yamaoka, S., Horaguchi, Y., Kasanami, Y., Sekiguchi,
F., Tsubota, M.,
Yoshida, S., Nishikawa, H. Kawabata,
A.*, Toyooka, N.* (2018) Design and synthesis of novel
anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium
channel blockers. Bioorg.
Med. Chem., 26, 4410-4427. PubMed
46.
Sekiguchi,
F.,
Fujita, T., Deguchi, T., Yamaoka, S., Tomochika, K., Tsubota, M., Ono,
S., Horaguchi, Y., Ichii, M., Ichikawa, M., Ueno, Y., Koike, N., Tanino, T.,
Nguyen, H.D., Okada, T., Nishikawa, H., Yoshida, S., Ohkubo, T., Toyooka, N.,
Murata, K., Matsuda, H., Kawabata,
A.* (2018) Blockade of T-type calcium channels by 6-prenylnaringenin, a
hop component, alleviates neuropathic and visceral pain in mice. Neuropharmacology,
138, 232-244. PubMed
47.
Sekiguchi,
F.,
Tsubota, M., Kawabata, A.* (2018)
Involvement of voltage-gated calcium channels in inflammation and inflammatory
pain. Biol. Pharm. Bull.,
41, 1127-1134. PubMed (Review)
48.
Tsubota,
M.,
Okawa, Y., Irie, Y., Maeda, M., Ozaki, T., Sekiguchi,
F., Ishikura, H., Kawabata,
A.* (2018) Involvement of the cystathionine-γ-lyase/Cav3.2
pathway in substance P-induced bladder pain in the mouse, a model for
nonulcerative bladder pain syndrome. Neuropharmacology,
133, 254-263. PubMed
49.
Tsubota,
M.,
Ozaki, T. (co-first author), Hayashi, Y., Okawa, Y., Fujimura, A., Sekiguchi, F., Nishikawa, H., Kawabata, A.* (2018)
Prostanoid-dependent bladder pain caused by proteinase-activated receptor-2
activation in mice: Involvement of TRPV1 and T-type Ca2+ channels. J. Pharmacol. Sci.,
136, 46-49. PubMed
50.
Tsujita, R., Tsubota, M. (co-first author), Hayashi, Y. (co-first
author), Saeki, H., Sekiguchi, F.,
Kawabata, A.* (2018) Role of
thrombin in soluble thrombomodulin-induced suppression of peripheral
HMGB1-mediated allodynia in mice. J. Neuroimmune Pharmacol.,
13, 179-188. PubMed
51.
Hayashi, Y., Tsujita, R. (co-first
author), Tsubota, M.
(co-first author), Saeki, H., Sekiguchi,
F., Honda, G., Kawabata, A.*
(2018) Human soluble thrombomodulin-induced blockade of peripheral
HMGB1-dependent allodynia in mice requires both the lectin-like and EGF-like
domains. Biochem. Biophys. Res. Commun.,
495, 634-638. PubMed
52.
Ozaki, T., Matsuoka, J., Tsubota, M., Tomita, S., Sekiguchi, F., Minami, T., Kawabata, A.* (2018) Zinc
deficiency promotes cystitis-related bladder pain by enhancing function and
expression of Cav3.2 in mice. Toxicology, 393, 102-112. PubMed
53.
Ozaki, T., Tsubota, M., Sekiguchi,
F., Kawabata, A.*
(2018) Involvement of NF-κB in the upregulation of cystathionine-γ-lyase, a
hydrogen sulfide-forming enzyme, and bladder pain accompanying cystitis in
mice. Clin. Exp. Pharmacol.
Physiol., 45, 355-361. PubMed
54.
Irie, Y., Tsubota, M. (co-first author), Ishikura, H., Sekiguchi, F., Terada, Y.,
Tsujiuchi, T., Liu, K., Nishibori, M., Kawabata,
A.* (2017) Macrophage-derived HMGB1 as a pain mediator in the early
stage of acute pancreatitis in mice: targeting RAGE and CXCL12/CXCR4 axis. J. Neuroimmune Pharmacol.,
12, 693-707. PubMed
55.
関口富美子、川畑篤史* (2017) 硫化水素(H2S)分子によるイオンチャネル機能制御と病態への関与.硫酸と工業, 80 (5), 61-70. (Review)
56.
Tsubota,
M.,
Miyamoto, T., Hiruma, S., Saeki, H., Miyazaki, T., Sekiguchi, F., Funakami, Y., Kawabata, A.* (2017) Repeated cold stress reduces cyclophosphamide-induced
cystitis/bladder pain and macrophage activity in mice. Pharmacology, 99, 286-290. PubMed
57.
坪田真帆、川畑篤史* (2017) トロンボモジュリンアルファの内臓痛治療への応用.潰瘍, 44,
48-53. (Review)
58.
Fukami, K., Asano, E., Ueda, M., Sekiguchi, F., Yoshida, S., Kawabata, A.* (2017) High
glucose induces N-linked glycosylation-mediated functional upregulation and
overexpression of Cav3.2 T-type calcium channels in neuroendocrine-like
differentiated human prostate cancer cells. J. Pharmacol. Sci.,
133, 57-60. PubMed
59.
Miyamoto, T., Funakami, Y., Kawashita, E.,
Tomita, S., Nomura, A., Sugimoto, N., Saeki, H., Tsubota, M., Ichida, S., Kawabata, A.* (2017) Enhanced hyperthermic responses to
lipopolysaccharide in mice exposed to repeated cold stress. Pharmacology, 99, 172-178. PubMed
60.
Miyamoto, T., Funakami, Y., Kawashita, E.,
Nomura, A., Sugimoto, N., Saeki, H., Tsubota,
M., Ichida, S., Kawabata, A.*
(2017) Repeated cold stress enhances the acute restraint stress-induced
hyperthermia in mice. Biol.
Pharm. Bull., 40, 1-6. PubMed
61.
Terada, Y., Tsubota, M., Sugo, H., Wakitani, K., Sekiguchi, F., Wada, K., Takada, M., Oita, A., Kawabata, A.* (2017) Tacrolimus
triggers TRPV1-dependent relapse of pancreatitis-related pain in mice. Pharmacology, 99, 281-285. PubMed
62.
Terada, Y., Wada, K.*, Matsuda, S.,
Kuwahara, T., Kawabata, A.,
Takada, M., Watanabe, T., Nakajima, S., Sato, T., Seguchi, O., Yanase, M.,
Fukushima, N., Nakatani, T. (2017) Circadian pharmacokinetics and limited
sampling strategy of everolimus in heat transplant patients. Int. J. Clin. Pharmacol. Ther.,
55 (1), 1-8. PubMed
63.
Fukami, K., Sekiguchi, F., Kawabata,
A.* (2016) Hydrogen sulfide and T-type Ca2+ channels in pain
processing, neuronal differentiation and neuroendocrine secretion. Pharmacology, 99, 176-203. PubMed (Review)
64.
坪田真帆、川畑篤史* (2016) 膵臓の疼痛における侵害受容体の関与と治療への展望.(特集:膵疾患の疼痛治療のup-to-date ―疼痛の発生メカニズムから疾患別治療まで)胆と膵, 37, 1535-1539. (Review)
65.
Nishida, T., Tsubota, M. (co-first author), Kawaishi, Y., Yamanishi, H.,
Kamitani, N., Sekiguchi, F.,
Ishikura, H., Liu, K., Nishibori, M., Kawabata,
A.* (2016) Involvement of high mobility group box 1 in the development
and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology, 365, 48-58. PubMed
66.
Sekiguchi,
F.,
Kawara, Y., Tsubota, M.,
Kawakami, E., Ozaki, T., Kawaishi, Y., Tomita, S., Kanaoka, D., Yoshida, S.,
Ohkubo, T., Kawabata, A.* (2016)
Therapeutic potential of RQ-00311651, a novel T-type Ca2+ channel
blocker, in distinct rodent models for neuropathic and visceral pain. Pain, 157,
1655-1665. PubMed
67.
Mitani, K., Sekiguchi, F., Maeda, T., Tanaka, Y., Kawabata, A.* (2016) The prostaglandin E2/EP4
receptor/cyclic AMP/T-type Ca2+ channel pathway mediates neuritogenesis
in sensory neuron-like ND7/23 cells. J. Pharmacol. Sci.,
130, 177-180. PubMed
68.
Sekiguchi,
F.,
Sekimoto, T., Ogura, A., Kawabata,
A.* (2016) Endogenous hydrogen sulfide enhances cell proliferation of
human gastric cancer AGS cells. Biol. Pharm. Bull.,
39, 887-890. PubMed
69.
Yamasoba, D., Tsubota, M., Domoto, R., Sekiguchi, F., Nishikawa, H., Liu, K., Nishibori, M., Ishikura,
H., Yamamoto, T., Taga, A., Kawabata,
A.* (2016) Peripheral HMGB1-induced hyperalgesia in mice: redox
state-dependent distinct roles of RAGE and TLR4. J. Pharmacol. Sci.,
130, 139-142. PubMed
70.
Aoki, Y., Tsubota, M., Nishimoto, Y., Maeda, Y., Sekiguchi, F., Kawabata,
A.* (2016) Selective sensitization of C-fiber nociceptors by hydrogen
sulfide. J. Pharmacol. Sci.,
130, 38-41. PubMed
71.
Nagai, N., Yoshioka, C., Ito, Y.*,
Funakami, Y., Nishikawa, F., Kawabata,
A. (2015) Intravenous administration of cilostazol nanoparticles
ameliorates acute ischemic stroke in a cerebral ischemia/reperfusion-induced
injury model. Int. J. Mol. Sci., 16,
29329-29344. PubMed
72.
Fukami, K., Sekiguchi, F., Yasukawa, M., Asano, E., Kasamatsu, R., Ueda,
M., Yoshida, S., Kawabata, A.*
(2015) Functional upregulation of the H2S/Cav3.2 channel
pathway accelerates secretory function in neuroendocrine-differentiated human
prostate cancer cells. Biochem.
Pharmacol. 97, 300-309. PubMed
73.
Terada, Y., Kawabata, A.* (2015) H2S and pain: a novel aspect
for processing of somatic, visceral and neuropathic pain signals. In Chemistry, Biochemistry and Pharmacology of Hydrogen
Sulfide, edited by Moore, P.K. and Whiteman, M., Springer, Handbook of Experimental Pharmacology 230: 217-230.
PubMed (Book Chapter / Review)
74.
Fukami, K., Kawabata, A.* (2015) Hydrogen sulfide and neuronal
differentiation: focus on Ca2+ channels. Nitric Oxide, 46, 50-54. PubMed (Review)
75.
Murakami-Nakayama, M., Tsubota, M., Hiruma, S., Sekiguchi, F., Matsuyama, K.,
Kimura, T., Moriyama, M., Kawabata,
A.* (2015) Polaprezinc attenuates cyclophosphamide-induced cystitis and
related bladder pain in mice. J. Pharmacol. Sci.,
127, 223-228. PubMed
76.
Terada, Y., Fujimura, M., Nishimura, S., Tsubota, M., Sekiguchi, F., Kawabata, A.* (2015) Roles of Cav3.2
and TRPA1 channels targeted by hydrogen sulfide in pancreatic nociceptive
processing in mice with or without acute pancreatitis. J. Neurosci. Res., 93, 361-369. PubMed
77.
Takechi, M.*, Wada, T., Yagi, H., Masuko,
T., Kawabata, A. (2015) Ouabain
exerts cytoprotection by diminishing the intracellular K+
concentration increase caused by distinct stressful stimuli in human leukemic
cells. J. Pharm. Pharmacol., 67,
126-132. PubMed
78.
Maeda, Y., Sekiguchi, F., Yamanaka, R., Sugimoto, R., Yamasoba, D.,
Tomita, S., Nishikawa, H., Kawabata,
A.* (2015) Mechanisms for proteinase-activated receptor 1-triggered
prostaglandin E2 generation in mouse osteoblastic MC3T3-E1 cells. Biol. Chem., 396, 153-162. PubMed
79.
坪田真帆*、川畑篤史 (2014) 結腸の疼痛および炎症におけるガス状情報伝達物質硫化水素の役割.Yakugaku Zasshi, 134,
1245-1252. PubMed (Review)
80.
Sekiguchi,
F.,
Miyamoto, Y., Kanaoka, D., Ide, H., Yoshida, S., Ohkubo, T., Kawabata, A.* (2014) Endogenous and exogenous hydrogen sulfide facilitates
T-type calcium channel currents in Cav3.2-expressing HEK293 cells. Biochem. Biophys. Res. Commun., 445, 225-229. PubMed
81.
Tanaka, J., Yamaguchi, K., Ishikura, H., Tsubota, M., Sekiguchi, F., Seki, Y.,
Tsujiuchi, T., Murai, A., Umemura, T., Kawabata,
A.* (2014) Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin
in mice with cyclophosphamide-induced cystitis. Neuropharmacology, 79, 112-118. PubMed
82.
Terada, Y., Fujimura, M., Nishimura, S., Tsubota, M., Sekiguchi, F., Nishikawa, H. and
Kawabata, A.* (2013)
Contribution of TRPA1 as a downstream signal of proteinase-activated receptor-2
to pancreatic pain. J.
Pharmacol. Sci., 123, 284-287. PubMed
83.
Tanaka, J., Seki, Y., Ishikura, H., Tsubota, M., Sekiguchi, F., Yamaguchi, K.,
Murai, A., Umemura, T. and Kawabata,
A.* (2013) Recombinant human soluble thrombomodulin prevents peripheral
HMGB1-dependent hyperalgesia in rats. Br. J. Pharmacol., 170,
1233-1241. PubMed
84.
Sekiguchi,
F.
and Kawabata, A.* (2013)
T-type calcium channels: functional regulation and implication in pain
signaling. J. Pharmacol. Sci.,
122, 244-250. PubMed
(Review)
85.
Nishikawa, H., Hayashi, H., Kubo, S., Tsubota-Matsunami, M., Sekiguchi, F., and Kawabata, A.* (2013) Inhibition
by hydrogen sulfide of rabbit platelet aggregation and calcium mobilization. Biol. Pharm. Bull., 36, 1278-1282. PubMed
86.
Nakayama, M.*, Fujiwara, M., Nakamura, T.,
Azuma, T., Matzno, S., Kamikonya, N., Kimura, T., Matsuyama, K., Kawabata, A. (2013) Stability of
polaprezinc-containing oral rinse and its clinical effectiveness against
radiotherapy-induced oral mucositis. Jpn. J. Drug
Inform., 15, 133-138.
87.
中山雅裕*、中村豪志、東剛史、志方敏幸、川畑篤史、松山賢治、冨土原将之、上紺屋憲彦、木村健. (2013 ) ポラプレジンク含嗽液の新たな基材に関する検討.医薬品情報学, 15, 13-17.
88.
Takahashi, T., Okubo, K., Kojima, S.,
Nishikawa, H., Takemura, M., Tsubota-Matsunami,
M., Sekiguchi, F. and
Kawabata, A.* (2013) Antihyperalgesic effect of buprenorphine involves
nociceptin/orphanin FQ peptide receptor activation in rats with spinal nerve injury-induced
neuropathy.
J. Pharmacol. Sci.,
122, 51-54. PubMed
89.
川畑篤史*. (2013 ) Cav3.2 T型カルシウムチャネルを標的とした癌化学療法誘起神経障害性疼痛の治療戦略.日薬理誌, 141,
81-84. PubMed (Review)
90.
Sekiguchi,
F.,
Aoki, Y., Nakagawa, M., Kanaoka, D., Nishimoto, Y., Tsubota-Matsunami, M., Yamanaka, R., Yoshida, S. and Kawabata, A.* (2013)
AKAP-dependent sensitization of Cav3.2 channels via the EP4
receptor/cyclic AMP pathway mediates prostaglandin E2-induced
mechanical hyperalgesia. Br.
J. Pharmacol., 168, 734-745. PubMed
91.
Sekiguchi,
F.,
Matsumoto, Y., Maeda, Y., Tsubota-Matsunami,
M., Nishikawa, H. and Kawabata,
A.* (2012) Biological activity of Helicobactor pylori components in
mammalian cells: is it independent of proteinase-activated recetpros? J. Physiol. Pharmacol.,
63, 571-576. PubMed
92.
Tsubota-Matsunami,
M.,
Noguchi, Y., Okawa, Y., Sekiguchi, F.
and Kawabata, A.* (2012) Colonic
hydrogen sulfide-induced visceral pain and referred hyperalgesia involve
activation of both Cav3.2 and TRPA1 channels in mice. J. Pharmacol. Sci.,
119, 293-296. PubMed
93.
Matsunami,
M.,
Miki, T., Nishiura, K., Hayashi, Y., Okawa, Y., Nishikawa, H., Sekiguchi, F., Kubo, L., Ozaki,
T., Tsujiuchi, T. and Kawabata, A.*
(2012) Involvement of the endogenous hydrogen sulfide/Cav3.2 T-type
Ca2+ channel pathway in cystitis-related bladder pain in mice. Br. J. Pharmacol., 167,
917-928. PubMed
94.
Kawabata,
A.*
and Matsunami, M. (2012)
Roles of the hydrogen sulfide/T-type calcium channel system in somatic and
visceral pain processing. In Cell/Tissue
Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract:
Mechanisms, Prevention and Treatment, edited by Filaretova, L.P.
and Takeuchi, K., Front. Gastrointest. Res., Basel, Karger (vol 30), pp212-218. (Book Chapter)
95.
Matsunami,
M.,
Kirishi, S., Okui, T. and Kawabata,
A.* (2012) Hydrogen sulfide-induced colonic mucosal cytoprotection
involves T-type calcium channel-dependent neuronal excitation in rats. J. Physiol. Pharmacol.,
63, 61-68. PubMed
96.
Okubo, K., Matsumura, M., Kawaishi, Y.,
Aoki, Y., Matsunami, M.,
Okawa, Y., Sekiguchi, F. and Kawabata, A.* (2012) Hydrogen
sulfide-induced mechanical hyperalgesia and allodynia require activation of
both Cav3.2 and TRPA1 channels in mice. Br. J. Pharmacol., 166,
1738-1743. PubMed
97.
Okubo, K., Nakanishi, H., Matsunami, M., Shibayama, H. and
Kawabata, A.* (2012) Topical
application of disodium isostearyl 2-O-L-ascorbyl phosphate, an amphiphilic
ascorbic derivative, reduces neuropathic hyperalgesia in rats. Br. J. Pharmacol., 166,
1058-1068. PubMed
98.
Kurokawa, Y., Sekiguchi, F., Kubo, S., Yamasaki, Y., Matsuda, S., Okamoto,
Y., Sekimoto, T., Fukatsu, A., Nishikawa, H., Kume, T., Fukushima, N., Akaike,
A. and Kawabata, A.* (2011)
Involvement of ERK in NMDA receptor-independent cortical neurotoxicity of
hydrogen sulfide. Biochem. Biophys. Res.
Commun., 414, 727-732. PubMed
99.
大久保寿政、川畑篤史* (2011) 神経障害性疼痛における硫化水素の役割.ペインクリニック, 32, 1464-1471. (Review)
100. Okubo,
K., Takahashi, T., Sekiguchi, F.,
Kanaoka, D., Matsunami, M.,
Ohkubo, T., Yamazaki, J., Fukushima, N., Yoshida, S. and Kawabata, A.* (2011) Inhibition of T-type calcium channels
and hydrogen sulfide-forming enzyme reverses paclitaxel-evoked neuropathic
hyperalgesia in rats. Neuroscience,
188, 148-156. PubMed
101. Matsunami, M.,
Kirishi, S., Okui, T. and Kawabata,
A.* (2011) Chelating luminal zinc mimics hydrogen sulfide-evoked
colonic pain in mice: possible involvement of T-type calcium channels. Neuroscience, 181: 257-264. PubMed
102. Miki,
T., Matsunami, M., Nakamura,
S., Okada, H., Matsuya, H. and Kawabata,
A.* (2011) ONO-8130, a selective prostanoid EP1 receptor antagonist,
relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain, 152, 1373-1381. PubMed
103. Kawabata, A.* (2011)
Prostaglandin E2 and pain: an update. Biol. Pharm. Bull.,
34, 1170-1173. (Review) PubMed
104. Kawabata, A.* (2011)
Lipid Mediators and Pain Signaling: Foreword. Biol. Pharm. Bull.,
34, 1153. (Foreword) PubMed
105. Sekiguchi, F., Ohi,
A., Maeda, Y., Takaoka, K., Sekimoto, T., Nishikawa, H. and Kawabata, A.* (2011) Delayed
production of arachidonic acid contributes to the delay of proteinase-activated
receptor-1 (PAR1)-triggered prostaglandin E2 release in rat gastric
epithelial RGM1 cells. J.
Cell. Biochem., 112, 909-1015.
PubMed
106. Nishimura,
S. Ishikura, H., Matsunami, M.,
Shinozaki, Y., Sekiguchi, F.,
Naruse, M., Kitamura, T., Akashi, R., Matsumura, K. and Kawabata, A.* (2010) The proteinase/proteinase-activated receptor-2/transient receptor
potential vanilloid-1 cascade impacts pancreatic pain in mice. Life Sci., 87, 643-650. PubMed
107. Moriyuki,
K., Sekiguchi, F., Matsubara,
K., Nishikawa, H. and Kawabata, A.* (2010)
Curcumin inhibits the proteinase-activated receptor-2-triggered prostaglandin E2
production by suppressing COX-2 upregulation and Akt-dependent activation of
NF-κB in human lung epithelial cells. J. Pharmacol. Sci.,
114, 225-229. PubMed
108. Fukushima,
O., Nishimura, S., Matsunami, M.,
Aoki, Y., Nishikawa, H., Ishikura, H. and Kawabata,
A.* (2010) Phosphorylation of
ERK in the spinal dorsal horn following pancreatic pro-nociceptive stimuli with
proteinase-activated receptor-2 agonists and hydrogen sulfide in rats: evidence
for involvement of distinct mechanisms. J.
Neurosci. Res., 88, 3198-3205. PubMed
109. Tarui,
T., Fukami, K., Nagasawa, K., Yoshida, S., Sekiguchi,
F. and Kawabata, A.*
(2010) Involvement of Src kinase in T-type calcium channel-dependent neuronal
differentiation of NG108-15 cells by hydrogen sulfide. J. Neurochem., 114, 512-519. PubMed
110. Takahashi,
T., Aoki, Y., Okubo, K., Maeda, Y., Sekiguchi,
F., Mitani, K., Nishikawa, H. and Kawabata,
A.* (2010) Upregulation of Cav3.2 T-type calcium channels
targeted by endogenous hydrogen sulfide contributes to maintenance of
neuropathic pain. Pain, 150,
183-191. PubMed
111. Takaoka,
K., Sekiguchi, F., Shigi, H.,
Maeda, Y., Nishikawa, H. and Kawabata,
A.* (2010) Opposite effects of two thiazolidinediones, ciglitazone and
troglitazone, on proteinase-activated receptor-1-triggered prostaglandin E2
release. Toxicology, 268, 40-45. PubMed
112.
Moriyuki, K., Sekiguchi, F., Matsubara, K., Nishikawa, H. and Kawabata, A.* (2009)
PAR2-triggered prostaglandin E2 release, but not cyclooxygenase-2
upregulation, requires activation of the phosphatidylinositol 3-kinase/Akt/NFκB
pathway in human alveolar epithelial cells. J. Pharmacol. Sci.,
111, 269-275.
PubMed
113.
Kanke, T., Kabeya, M., Kubo, S., Kondo,
S., Yasuoka, K., Tagashira, J., Ishiwata, H., Saka, M., Furuyama, T.,
Nishiyama, T., Doi, T., Hattori, Y., Kawabata,
A., Cunningham, M., Plevin, R.* (2009) Novel antagonists for
proteinase-activated receptor 2: inhibition of cellular and vascular responses
in vitro and in vivo. Br.
J. Pharmacol.,158, 361-371.
PubMed
114.
Taniguchi, E., Matsunami, M., Kimura, T., Yonezawa, D., Ishiki, T., Sekiguchi, F., Nishikawa, H.,
Maeda, Y., Ishikura, H., Kawabata, A.* (2009) Rhodanese, but
not cystathionine-γ-lyase, is associated with dextran sulfate sodium-evoked
colitis in mice: a sign of impaired colonic sulfide detoxification? Toxicology, 264, 96-103.
PubMed
115.
川畑篤史*.(2009) 気体メディエーターとしての硫化水素の神経機能.脳21, 12,
239-245. (Review)
116. Nishimura, S.,
Fukushima, O., Ishikura, H., Takahashi, T., Matsunami, M., Tsujiuchi, T., Sekiguchi, F., Naruse, M., Kamanaka, Y. and Kawabata, A.* (2009) Hydrogen sulfide as a novel mediator for
pancreatic pain in rodents. Gut,
58, 762-770. PubMed Outstanding
paper
117.
Maeda, Y., Aoki, Y., Sekiguchi, F., Matsunami,
M., Takahashi, T., Nishikawa, H. and Kawabata, A.* (2009) Hyperalgesia induced by spinal and peripheral
hydrogen sulfide: evidence for involvement of Cav3.2 T-type calcium
channels. Pain, 142, 127-132. PubMed
118.
Nagasawa, K., Tarui, T., Yoshida, S., Sekiguchi, F., Matsunami, M., Ohi, A., Fukami,
K., Ichida, S., Nishikawa, H. and Kawabata,
A.* (2009) Hydrogen sulfide evokes neurite outgrowth and expression of
high-voltage-activated Ca2+ currents in NG108-15 cells: involvement
of T-type Ca2+ channels. J.
Neurochem., 108, 676-684. PubMed
119. Matsunami, M., Tarui, T., Mitani,
K., Nagasawa, K., Fukushima, O., Okubo, K., Yoshida, S., Takemura, M. and Kawabata,
A.* (2009) Luminal hydrogen
sulfide plays a pronociceptive role in mouse colon. Gut,
58, 751-761. PubMed Outstanding
paper
120.
Hirano, K.* and Kawabata, A. (2008) Basic and translational research on
proteinase-activated receptors: Preface. J. Pharmacol. Sci.,
108, 406-407. PubMed (Preface)
121.
Tanaka, Y., Sekiguchi, F.,
Hong, H. and Kawabata, A.* (2008) PAR2 triggers IL-8 release via
MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells. Biochem. Biophys. Res. Commun., 377,
622-626. PubMed
122.
関口富美子,川畑篤史.(2008) Protease-activated receptor シグナル.救急・集中治療, 20 (9-10), 1297-1303. (Review)
123.
Kawabata, A.*, Matsunami,
M. and Sekiguchi, F. (2008) Gastrointestinal roles for proteinase-activated
receptors in health and disease. Br. J. Pharmacol., 153,
S230-S240. (Review) PubMed
124.
Nagataki, M., Moriyuki, K., Sekiguchi,
F. and Kawabata, A.* (2008) Evidence that PAR2-triggered
prostaglandin E2 (PGE2) formation involves the
ERK-cytosolic phospholipase A2-COX-1-microsomal PGE synthase-1
cascade in human lung epithelial cells. Cell
Biochem. Funct., 26, 279-282. PubMed
125.
Moriyuki, K., Nagataki, M., Sekiguchi,
F., Nishikawa, H. and Kawabata, A.* (2008) Signal
transduction for formation/release of interleukin-8 caused by a PAR2-activating
peptide in human lung epithelial cells. Regul.
Pept, 145, 42-48. PubMed
126. Kubo,
S., Kajiwara, M. and Kawabata, A.*
(2007) Dual modulation of the tension of isolated gastric artery and gastric
mucosal circulation by hydrogen sulfide in rats. Inflammopharmacology,
15, 288-292.
127. Sekiguchi, F.,
Takaoka, K. and Kawabata, A.*
(2007) Proteinase-activated receptors in the gastrointestinal system: a
functional linkage to prostanoids. Inflammopharmacology,
15, 246-251.
(Review)
128. Kubo,
S., Kurokawa, Y., Doe, I., Masuko, T., Sekiguchi, F. and Kawabata,
A.* (2007) Hydrogen sulfide inhibits activity of three isoforms of
recombinant nitric oxide synthase. Toxicology,
241, 92-97.
129. 松波真帆,川畑篤史*.(2007) H2Sは痛みのメディエータか?.日薬理誌, 130, 436-437. (Review:最近の話題)
130. Yonezawa,
D., Sekiguchi, F., Miyamoto, M., Taniguchi, E., Honjo, M.,
Masuko, T., Nishikawa, H. and Kawabata, A.* (2007) A protective
role of hydrogen sulfide against oxidative stress in rat gastric mucosal
epithelium. Toxicology, 241,
11-18.
131. Kubo,
S., Doe, I., Kurokawa, Y. and Kawabata, A.* (2007) Hydrogen
sulfide causes relaxation in mouse bronchial smooth muscle. J. Pharmacol. Sci., 104, 392-396.
132. Kawabata,
A.*
(2007) Roles for H2S in Pain Processing: Response to Cunha and Verri.
Pain, 130, 302-303.
133. Ishikura,
H., Nishimura, S., Matsunami, M., Tsujiuchi, T., Ishiki, T.,
Sekiguchi, F., Naruse, M., Nakatani, T., Kamanaka, Y. and Kawabata,
A.* (2007) The proteinase inhibitor camostat mesilate suppresses
pancreatic pain in rodents. Life Sci.,
80, 1999-2004.
134. Kawabata,
A.*,
Ishiki, T., Nagasawa, K., Yoshida, S., Maeda, Y., Takahashi, T., Sekiguchi,
F., Wada, T., Ichida, S. and Nishikawa, H. (2007) Hydrogen sulfide as a
novel nociceptive messenger. Pain,
132, 74-81.
135. Kubo,
S., Doe, I., Kurokawa, Y., Nishikawa, H. and Kawabata, A.* (2007) Direct
inhibition of endothelial nitric oxide synthase by hydrogen sulfide:
contribution to dual modulation of vascular tension. Toxicology, 232, 138-146.
136. Sekiguchi, F., Saito,
S., Takaoka, K., Hayashi, H., Nagataki, M., Nagasawa, K., Nishikawa, H.,
Matsui, H. and Kawabata, A.*
(2007) Mechanisms for prostaglandin E2 formation caused by
proteinase-activated receptor-1 activation in rat gastric mucosal epithelial
cells. Biochem. Pharmacol., 73,
103-114.
137.
Kubo, S., Ishiki, T., Doe, I., Sekiguchi, F., Nishikawa, H.,
Kawai, K., Matsui, H. and Kawabata,
A.* (2006) Distinct activity of
peptide mimetic intracellular ligands (pepducins) for proteinase-activated
receptor-1 in multiple cells/tissues. Ann. NY
Acad. Sci., 1091, 445-459.
138.
松波真帆,関口富美子,川畑篤史*.(2006) プロテアーゼ活性化受容体.日薬理誌, 128, 434-436. (Review:キーワード解説)
139.
川畑篤史* (2006). PARの消化管機能.日薬理誌, 128,
82-87. (Review)
140.
Kawabata,
A.*,
Kawao, N., Kitano, T., Matsunami, M., Satoh, R., Ishiki, T., Masuko,
T., Kanke, T. and Saito N. (2006). Colonic hyperalgesia triggered by
proteinase-activated receptor-2 in mice: involvement of endogenous bradykinin. Neurosci. Lett., 402, 167-172.
141.
Kawabata,
A.*,
Kawao, N., Hironaka, Y., Ishiki, T., Matsunami, M. and Sekiguchi, F. (2006).
Antiallodynic effect of etidronate, a bisphosphonate, in rats with
adjuvant-induced arthritis: involvement of ATP-sensitive K+
channels. Neuropharmacology, 51,
182-190.
142.
Kawabata,
A.*,
Matsunami, M., Tsutsumi, M., Ishiki, T., Fukushima, O., Sekiguchi, F., Kawao, N.,
Minami, T., Kanke, T. and Saito, N. (2006) Suppression of pancreatitis-related
allodynia/hyperalgesia by proteinase-activated receptor-2 in mice. Br. J. Pharmacol., 148, 54-60.
143.
川畑篤史* (2006). PAR-2と痛み.日薬理誌, 127,
133-136. (Review)
144. Sekiguchi, F.,
Hasegawa, N., Inoshita, K., Yonezawa, D., Inoi, N., Kanke, T., Saito, N. and Kawabata, A.* (2006) Mechanisms
for modulation of mouse gastrointestinal motility by proteinase-activated
receptor (PAR)-1 and -2 in vitro. Life Sci., 78, 950-957.
145.
Kawao, N., Nagataki, M., Nagasawa, K.,
Kubo, S., Cushing, K., Wada, T.,
Sekiguchi, F., Ichida, S., Hollenberg, M.D., MacNaughton, W.K.,
Nishikawa, H. and Kawabata, A.* (2005)
Signal transduction for proteinase-activated receptor-2-triggered prostaglandin
E2 formation in human lung epithelial cells. J. Pharmacol. Exp. Ther., 315, 576-589.
146.
Nishikawa, H. and Kawabata, A.* (2005) PAR-2 as a target for gastric mucosal
protection. Drugs of Future, 30, 793-798.
(Review)
147.
川畑篤史* (2005).知覚神経・TRPV1の急性膵炎発症への関与.G. I. Research, 13,
387-392. (Review)
148.
西川裕之, 川畑篤史*
(2005). 消化器系におけるPARの役割.Surgery Frontier , 12, 135-143. (Review)
149.
関口富美子*
(2005).
Protease-activated receptors (PARs)をターゲットとしたアゴニスト/アンタゴニストの開発と消化器系疾患に対する治療応用の可能性. Yakugaku Zasshi, 125,
491-498. (Review)
150.
Kanke, T.*, Ishiwata, H., Kabeya, M.,
Saka, M., Doi, T., Hattori, Y., Kawabata,
A. and Plevin, R. (2005)
Binding of a highly potent protease-activated receptor-2 (PAR2) activating
peptide, [3H]-2-furoyl-LIGRL-NH2, to human PAR2. Br. J. Pharmacol., 145,
255-263.
151.
Kawabata, A.*,
Oono, Y., Yonezawa, D., Hiramatsu, K., Inoi, N., Sekiguchi, F., Honjo, M., Hirofuchi, M., Kanke, T. and
Ishiwata, H. (2005) 2-furoyl-LIGRL-NH2, a potent agonist for proteinase-activated
receptor-2, as a gastric mucosal cytoprotective agent. Br. J. Pharmacol., 144, 212-219.
152.
Kawabata,
A.*
and Kawao, N. (2005) Physiology and pathophysiology of proteinase-activated
receptors (PARs): PARs in the respiratory system: cellular signaling and
physiological/pathological roles. J. Pharmacol. Sci.,
97, 20-24. (Review)
153.
Kanke, T.*, Takizawa, T., Kabeya, M. and Kawabata, A. (2005) Physiology
and pathophysiology of proteinase-activated receptors (PARs):
Proteinase-activated receptor-2 (PAR-2) as a potential therapeutic target. J. Pharmacol. Sci., 97, 38-42. (Review)
154.
Nishikawa, H., Kawai, K., Tanaka, M.,
Ohtani, H., Tanaka, S., Kitagawa, C., Nishida, M., Abe, T., Araki, H. and Kawabata, A.* (2005).
Protease-activated receptor-2 (PAR-2)-related peptides induce tear secretion in
rats: involvement of PAR-2 and non-PAR-2 mechanisms. J. Pharmacol. Exp. Ther., 312, 324-331.
155.
Kimura, T., Arai,
M., Masuda, H. and Kawabata, A.*
(2004). Impact
of a pharmacist-implemented anemia management in outpatients with end-stage
renal disease in Japan. Biol. Pharm. Bull.,
27, 1831-1833.
156.
Kawabata,
A.*,
Nakaya, Y., Ishiki, T., Kubo, S., Kuroda, R., Sekiguchi, F., Kawao, N., Nishikawa, H. (2004) Receptor-activating
peptides for PAR-1 and PAR-2 relax rat gastric artery via multiple mechanisms. Life Sci., 75, 2689-2702.
157.
Sekiguchi,
F.
and Kawabata, A.* (2004)
Protease-activated receptors (PARs) as therapeutic targets: development of
agonists/antagonists and modulation of gastrointestinal functions. Drug Design Reviews, 1, 287-296. (Review)
158. 川畑篤史*
(2004) PAR (protease-activated receptor). 生体の科学 55,
520-521. (Review)
159. Kawabata, A.*, Kubo, S., Ishiki,
T., Kawao, N., Sekiguchi, F.,
Kuroda, R., Hollenberg, M.D., Kanke, T. and Saito N. (2004) Proteinase-activated receptor-2-mediated
relaxation in mouse tracheal and bronchial smooth muscle: Signal transduction
mechanisms and distinct agonist sensitivity. J.
Pharmacol. Exp. Ther., 311, 402-410.
160. Kawabata, A.*, Itoh, H., Kawao,
N., Kuroda, R., Sekiguchi, F.,
Masuko, T., Iwata, K., Ogawa, A. (2004). Activation of trigeminal nociceptive
neurons by parotid PAR-2 activation in rats. NeuroReport,
15, 1617-1621.
161. Sekiguchi, F., Mita, Y., Kamanaka, Y., Kawao, N., Matsuya, H., Taga, C. and Kawabata, A.* (2004). The
potent iNOS inhibitor ONO-1714 inhibits nNOS and exerts antinociception in
rats. Neurosci. Lett., 365, 111-115.
162. Kawabata, A*, Kanke,
T., Yonezawa, D., Ishiki, T., Saka, M., Kabeya, M., Sekiguchi, F., Kubo, S., Kuroda, R., Iwaki, M., Katsura, K.
and Plevin, R (2004) Potent and metabolically stable agonists for
protease-activated receptor-2: Evaluation of activity in multiple assay systems
in vitro and in vivo. J.
Pharmacol. Exp. Ther., 309, 1098-1107.
163. Kawao,
N., Ikeda, H., Kitano, T., Kuroda, R., Sekiguchi,
F., Kataoka, K., Kamanaka, Y. and Kawabata,
A.* (2004) Modulation of capsaicin-evoked visceral pain and referred
hyperalgesia by protease-activated receptors 1 and 2. J.
Pharmacol. Sci., 94, 277-285.
164. Kawabata, A.*, Kubo,
S., Nakaya, Y., Ishiki, T., Kuroda, R., Sekiguchi,
F., Kawao, N. and Nishikawa, H. (2004). Distinct roles for
protease-activated receptors 1 and 2 in vasomotor modulation in rat superior
mesenteric artery. Cardiovasc. Res. 61, 683-692.
165. Kawabata, A.*, Nishikawa, H.,
Saitoh, H., Nakaya, Y., Hiramatsu, K., Kubo, S., Nishida,
M., Kawao, N., Kuroda, R., Sekiguchi,
F., Kinoshita, M., Kakehi, K., Arizono, N., Yamagishi, H. and Kawai, K.
(2004) A protective role of protease-activated receptor-1 in rat gastric
mucosa. Gastroenterology 126, 208-219. Breakthrough
paper
166. Kawao, N., Hiramatsu, K., Inoi, N.,
Kuroda, R., Nishikawa, H., Sekiguchi,
F. and Kawabata, A.* (2003) The PAR-1-activating peptide facilitates
pepsinogen secretion in rats. Peptides 24, 1449-1451.
167. Kamanaka, Y., Kawabata, A.*, Matsuya, H., Taga, C., Sekiguchi, F. and Kawao, N. (2003) Effect of a potent iNOS inhibitor
(ONO-1714) on acetaminophen-induced hepatotoxicity in the rat. Life Sci. 74, 793-802.
168. Kawabata,
A.*,
Nakaya, Y., Kuroda, R., Wakisaka, M., Masuko, T., Nishikawa, H. and Kawai, K.
(2003) Involvement of EDHF in the hypotension and increased gastric mucosal
blood flow caused by PAR-2 activation in rats. Br.
J. Pharmacol. 140, 247-254.
169. 黒田良太郎*,川畑篤史
(2003) 痛み情報伝達経路 −
末梢から大脳皮質まで.Yakugaku Zasshi 123, 533-546.
(Review)
170. Kawabata,
A.* (2003) Gastrointestinal functions
of proteinase-activated receptors. Life Sci.
74, 247-254. (Review)
171. 川畑篤史*,河尾直之
(2003) Protease-activated receptors と炎症.BIO Clinica 18, 551-555
(Review)
172. Nishikawa,
H. and Kawabata, A.* (2003) Modulation of gastric functions by
PARs. Drug Dev. Res. 60, 9-13. (Review)
173. 川畑篤史*
(2003) プロテアーゼ受容体PAR-2
(protease-activated receptor-2) の生理機能.日薬理誌 121, 411-420.
(Review)
174. Kawabata,
A.* (2002) Multiple roles for
protease-activated receptor-2 in gastric mucosa. Inflammopharmacology
10, 343-349. (Review)
175.
川畑篤史*
(2002) Protease-activated receptor-2 (PAR-2): 神経系,消化器系および血管系における役割.日本血栓止血学会誌 13, 467-476. (Review)
176. 川畑篤史*,黒田良太郎
(2002) 胃粘膜保護薬開発のための新しい標的分子としてのプロテアーゼ受容体PAR
(protease-activated receptor). 日薬理誌 120 (補冊1), 85P-87P. (Review)
177. Kawabata,
A.*,
Kuroda, R., Nishida, M., Nagata, N., Sakaguchi, Y., Kawao, N., Nishikawa, H.,
Arizono, N. and Kawai, K. (2002) Protease-activated receptor-2 (PAR-2) in the
pancreas and parotid gland: immunolocalization and involvement of nitric oxide
in the evoked amylase secretion. Life Sci.
71, 2435-2446.
178. Kawabata,
A.*,
Kawao, N., Itoh, H., Shimada, C., Takebe, K., Kuroda, R., Masuko, T., Kataoka,
K. and Ogawa, S. (2002) Role of N-methyl-D-aspartate receptors and the nitric
oxide pathway in nociception/hyperalgesia elicited by PAR-2 activation in mice
and rats. Neurosci. Lett. 329,
349-353.
179. 川畑篤史*
(2002) PAR (protease-activated receptor). 生体の科学 53,
345.
(Mini Review)
180. Nishikawa,
H., Kawai, K., Nishimura, S., Tanaka, S., Araki, H., Al-Ani, B., Hollenberg,
M.D., Kuroda, R. and Kawabata, A.* (2002) Suppression by
protease-activated receptor-2 activation of gastric acid secretion in rats. Eur. J. Pharmacol. 447, 87-90.
181. Gojyo,
F., Sugiyo, S., Kuroda, R., Kawabata, A., Varathan, V.,
Shigenaga, Y. and Takemura, M.* (2002) Effects of somatosensory cortical
stimulation on expression of c-Fos in rat medullary dorsal horn in response to
formalin-induced noxious stimulation. J.
Neurosci. Res., 68, 479-488.
182. Kawabata,
A.* (2002) PAR-2: structure, function
and relevance to human diseases of the gastric mucosa. Expert Reviews in Molecular Medicine (a Web
journal published by Cambridge University Press), 16 July,
http://www.expertreviews.org/02004799h.htm. (Review)
183. Kawao,
N., Shimada, C., Itoh, H., Kuroda, R. and Kawabata, A.* (2002)
Capsazepine inhibits thermal hyperalgesia but not nociception triggered by
protease-activated receptor-2 in rats. Jpn. J.
Pharmacol., 89, 184-187.
184. Kawabata,
A.*,
Kawao, N., Kuroda, R., Tanaka, A. and Shimada, C. (2002) The PAR-1-activating
peptide attenuates carrageenan-induced hyperalgesia in rats. Peptides 23, 1181-1183.
185. Kawao,
N., Sakaguchi, Y., Tagome, A., Kuroda, R., Nishida, S., Irimajiri, K.,
Nishikawa, H., Kawai, K., Hollenberg, M.D., and Kawabata, A.*
(2002) Protease-activated receptor-2 in the rat gastric mucosa:
immunolocalization and facilitation of pepsin/pepsinogen secretion. Br. J. Pharmacol., 135, 1292-1296.
186. Kawabata,
A.*,
Kawao, N., Kuroda, R., Itoh, H. and Nishikawa, H. (2002) Specific expression of
spinal Fos after PAR-2 stimulation in mast cell-depleted rats. NeuroReport, 13, 511-514.
187.
Kawabata, A.*,
Kinoshita, M., Kuroda, R. and Kakehi, K. (2002) Capsazepine partially inhibits
the neurally mediated gastric mucus secretion following activation of
protease-activated receptor-2. Clin. Exp.
Pharmacol. Physiol., 29, 360-361.
188. Morimoto,
N., Nakano, M., Kinoshita, M., Kawabata, A., Morita, M., Oda, Y.,
Kuroda, R. and Kakehi, K.* (2001) Specific distribution of sialic acids
in animal tissues as examined by LC-ESI-MS after derivatization with
1,2-diamino-4,5-methylenedioxybenzene. Anal.
Chem. 73, 5422-5428.
189. Kawabata,
A.*,
Kuroda, R., Nagata, N., Kawao, N., Masuko, T., Nishikawa, H. and Kawai, K.
(2001) In vivo evidence that protease-activated receptors 1 and 2
modulate gastrointestinal transit in the mouse. Br. J. Pharmacol. 133, 1213-1218.
190. Kawabata,
A.*, Kuroda, R., Morimoto, N., Kawao,
N., Masuko, T., Kakehi, K., Kataoka, K., Taneda, M., Nishikawa, H. and Araki,
H. (2001) Lipopolysaccharide-induced subsensitivity of protease-activated
receptor-2 in the mouse salivary glands in vivo. Naunyn-Schmiedeberg’s Arch. Pharmacol. 364,
281-284.
191. Kawabata, A.*, Kinoshita, M.,
Nishikawa, H., Kuroda, R., Nishida, M., Araki, H., Arizono, N., Oda, Y. and
Kakehi, K. (2001) The protease-activated receptor-2 agonist induces gastric
mucus secretion and mucosal cytoprotection. J.
Clin. Invest. 107, 1443-1450. Breakthrough
paper
192. Kuroda,
R., Kawao, N., Yoshimura, H., Umeda, W., Takemura, M., Shigenaga, Y. and Kawabata,
A.* (2001) Secondary somatosensory cortex stimulation facilitates the antinociceptive
effect of the NO synthase inhibitor through suppression of spinal nociceptive
neurons in the rat. Brain Res.
903, 110-116.
193. Kawabata,
A.*, Kuroda,
R., Nakaya, Y., Kawai, K., Nishikawa, H. and Kawao, N. (2001) Factor Xa-evoked
relaxation in rat aorta: involvement of PAR-2. Biochem.
Biophys. Res. Commun. 282,
432-435.
194.
Kawabata, A.*,
Kawao, N., Kuroda, R., Tanaka, A., Itoh, H. and Nishikawa, H. (2001) Peripheral
PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats. NeuroReport 12, 715-719.
195.
Kawabata, A.*,
Kuroda, R., Nakaya, Y., Kawao, N. Nishikawa, H. (2001) Ex vivo evidence
that the phosphodiesterase inhibitor IBMX attenuates the up-regulation of PAR-2
in the endotoxemic rat aorta. Thromb. Res.
101, 513-515.
196. 川畑篤史* (2001) 創薬の新たな標的分子としてのG蛋白共役型プロテアーゼ受容体PAR
(protease-activated receptor).Yakugaku Zasshi 121,
1-7. (Review)
197.
Kataoka,
K.*, Asai, T., Taneda, M., Ueshima, S., Matsuo, O., Kuroda, R., Kawabata,
A. and Carmeliet, P. (2000) Roles of urokinase type plasminogen
activator in a brain stab wound. Brain Res.
887, 187-190.
198.
Kawabata,
A.*, Kuroda, R., Kuroki,
N., Nishikawa, H. and Kawai, K. (2000) Dual modulation by thrombin of the
motility of rat oesophageal
muscularis mucosae via two
distinct protease-activated receptors (PARs): a novel role for PAR-4 as opposed
to PAR-1. Br. J. Pharmacol. 131, 578-584.
199.
Kinoshita, M.,
Inagake, K., Kawabata, A., Kuroda, R., Oda, Y. and Kakehi, K.*
(2000) Fluorometric determination of mucin-type glycoproteins by the galactose oxidase-peroxidase
method. Anal. Biochem. 284,
87-92.
200. Kawabata,
A., Morimoto, N., Oda, Y., Kinoshita,
M., Kuroda, R. and Kakehi, K.* (2000) Determination of mucin in salivary
glands using sialic acids as the marker by high performance liquid
chromatography with fluorometric detection. Anal.
Biochem. 283, 119-121.
201. Kawabata,
A.*,
Kuroda, R., Kuroki, N., Nishikawa, H., Kawai, K. and Araki, H. (2000)
Characterization of the protease-activated receptor-1-mediated contraction and relaxation
in the rat duodenal smooth muscle. Life Sci.
67, 2521-2530.
202. Kawabata,
A.*,
Nishikawa, H., Kuroda, R., Kawai, K. and Hollenberg, M.D. (2000)
Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic
exocrine secretion in vivo in rats and mice. Br.
J. Pharmacol. 129, 1808-1814.
203. Kawabata,
A.*,
Morimoto, N., Nishikawa, H., Kuroda, R., Oda, Y. and Kakehi, K. (2000)
Activation of protease-activated receptor-2 (PAR-2) triggers mucin secretion in
the rat sublingual gland. Biochem. Biophys.
Res. Commun. 270, 298-302.
204. Kuroda,
R., Kawabata, A.*, Kawao, N., Umeda, W., Takemura, M. and
Shigenaga, Y. (2000) Somatosensory cortex stimulation-evoked analgesia in rats:
potentiation by NO synthase inhibition.
Life Sci. 66, PL271-PL276.
205. Nishikawa,
H., Kawabata, A.*, Kawai, K. and Kuroda, R. (2000) Guinea pig
platelets do not respond to GYPGKF, a protease-activated receptor-4-activating
peptide: a property distinct from human platelets. Blood
Coag. Fibrinol. 11,
111-113.
206. Kawabata,
A.* and Kuroda, R. (2000)
Protease-activated receptor (PAR), a novel family of G protein-coupled seven
trans-membrane domain receptors: activation mechanisms and physiological roles.
Jpn. J. Pharmacol. 82, 171-174. (Review)
207. Nishikawa,
H., Kawabata, A.*, Kuroda, R., Nishida, M. and Kawai, K. (2000)
Characterization of protease-activated receptors in rat peritoneal mast
cells. Jpn. J. Pharmacol.
82, 74-77.
208.
Kawabata, A.*,
Kuroda, R., Nishikawa, H. and Kawai, K. (1999) Modulation by protease-activated
receptors of the rat duodenal motility in vitro: possible mechanisms underlying
the evoked contraction and relaxation. Br. J.
Pharmacol. 128, 865-872.
209.
川畑篤史*,黒田良太郎,Hollenberg, M.D.
(1999) プロテアーゼ受容体 (PAR) の生理的役割:特に消化器系機能への関与について.日薬理誌 114 (補冊1), 173P-179P. (Review)
210. Kawabata,
A.*,
Kuroda, R., Nishikawa, H., Asai, T., Kataoka, K. and Taneda, M. (1999)
Enhancement of vascular permeability by specific activation of
protease-activated receptor-1 in rat hindpaw: a protective role of endogenous
and exogenous nitric oxide. Br. J. Pharmacol. 126, 1856-1862.
211. Al-Ani,
B., Saifeddine, M., Kawabata, A. and Hollenberg, M.D.*
(1999) Proteinase activated receptor 2: role of extracellular loop 2 for
ligand-mediated activation. Br. J. Pharmacol. 128, 1105-1113.
212. Al-Ani,
B., Saifeddine, M., Kawabata, A., Renaux, B., Mokashi, S. and
Hollenberg, M.D.* (1999) Proteinase-activated receptor-2 (PAR2):
development of a ligand binding assay correlating with activation of PAR2
by PAR1- and PAR2-derived peptide ligands. J.
Pharmacol. Exp. Ther. 290,
753-760.
213. Kawabata,
A., Saifeddine, M., Al-Ani, B.,
Leblond, L. and Hollenberg, M.D.* (1999) Evaluation of
proteinase-activated receptor-1 (PAR1) agonists and antagonists
using a cultured cell receptor desensitization assay: Activation of PAR2
by PAR1-targeted ligands.
J. Pharmacol. Exp. Ther.
288, 358-370.
214. Kawabata,
A.*, Kuroda, R., Minami, T., Kataoka,
K. and Taneda, M. (1998) Increased vascular permeability by a specific agonist
of protease-activated receptor-2 in rat hindpaw. Br. J.
Pharmacol. 125, 419-422.
215. Minami,
T.*, Okazaki, J., Kawabata, A., Kuroda, R. and Okazaki, Y.
(1998) Penetration of cisplatin into mouse brain by lipopolysaccharide. Toxicology 130, 107-113.
216. Kawabata,
A.*, Hata, T., Kuroda, R. (1998) Cross
tolerance to environmental stress and endotoxin. Life
Sci. 62, PL327-PL333.
217. Kawabata,
A., Murakami, E., Iwaki, M., Ogiso,
T., Suzuki, S., Mishima, M., Takada, M. and Kakehi, K.* (1998)
Importance of clinical activities to job satisfaction in Japanese
pharmacists. Am. J. Health-Syst. Pharm.
55, 360-363.
218. Minami,
T.*, Okazaki, J., Kawabata, A., Kawaki, H., Okazaki, Y.
and Tohno, Y. (1998) Roles of
nitric oxide and prostaglandins in the increased permeability of the
blood-brain barrier caused by lipopolysaccharide. Environ. Toxicol. Pharmacol.
5, 35-41.
219. Kawabata,
A.* and Hata, T. (1998) Disseminated
intravascular coagulation (DIC)-like events produced by environmental stress
and by lipopolysaccharide: Nitric oxide as a common key molecule. In “The
Biology of Nitric Oxide Part 6”, edited by S. Moncada, N. Toda,
H. Maeda and E.A. Higgs, pp.220, Portland Press (London).
220. 川畑篤史* (1998) NOS発現部位からみたNOの役割 - 3.脳幹 - 内因性鎮痛物質とNO.Clinical Neuroscience 16, 775-777. (Review)